FDA Oncology Chief Says International Clinical Trials Should Be Priority

Seeking Alpha42minutes ago

Summit Lead Asset Approved in China for Lung Cancer

Seeking AlphaJun 1 08:19 ET

Here's How Much You Would Have Made Owning Viking Therapeutics Stock In The Last 5 Years

Viking Therapeutics (NASDAQ:VKTX) has outperformed the market over the past 5 years by 37.13% on an annualized basis producing an average annual return of 50.59%. Currently, Viking Therapeutics has a

BenzingaMay 31 17:00 ET

Summit Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/31/2024 49.68% Citigroup $7 → $13 Maintains Buy 05/07/2024 -19.4% Citigroup → $7 Initiates Coverage On

BenzingaMay 31 16:03 ET

Summit Therapeutics' Lung Cancer Therapy Ivonescimab Shows Improved Progression-Free Survival Versus Merck's Multi-Billion Keytruda In China Study

On Friday, Summit Therapeutics Inc (NASDAQ:SMMT) shares are trading lower after the company's stock closed 272.1% higher at $10.92 on Thursday.Thursday, Summit Therapeutics Inc (NASDAQ:SMMT) announced

BenzingaMay 31 10:21 ET

Summit -25%, Pares Gains as 'China-only' Trial Beats Merck's Keytruda

Seeking AlphaMay 31 08:59 ET